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p53 genotyping: A fortune-teller’s crystal ball or a viable prognostic tool?Katie S. Nason, MD, MPHIdeally, predictive biomarkers with associated targeted ther-
apies would be available for individualized treatment of
esophageal cancer, optimizing outcome and minimizingchemotherapy-associated risks. Unfortunately, clinically
relevant biomarker identification for esophageal cancer
has been elusive, more often resembling predictions from
a fortune-teller’s crystal ball than proving to be valid, clin-
ically useful prognostic tools. The quest continues, howev-
er, and the p53 (TP53) gene appears promising. One of the
most frequently mutated cancer-associated genes and a crit-
ical tumor suppressor gene involved in programed cell
death,1 multiple studies show a relationship between
TP53 mutation and response to chemotherapy, including
that of esophageal cancer. A recent meta-analysis of 28
studies with 1497 patients by Zhang and colleagues2
showed high response rates to chemotherapy-based treat-
ment regimens in tumors with low p53 protein expression
or wild-type p53. Despite statistically significant findings,
however, the conclusions were limited by tremendous het-
erogeneity across studies with respect to assessment of ther-
apeutic response, chemotherapy regimens (dose and type),gery c November 2014
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Sand use of radiation. Zhang and colleagues2 cautioned that
immunohistochemistry interpretation is highly susceptible
to interobserver differences and may have limited useful-
ness because of the instability of the wild-type protein.
There were also discrepancies between p53 protein levels
and p53 gene mutations when assessed with reverse tran-
scription polymerase chain reaction. They concluded that
predicting response to chemotherapy in esophageal cancer
may be possible by assessing pretreatment p53 status but
could not make a definitive statement.
To investigate further the prognostic capabilities of TP53,
the current study of Kandioler and colleagues, published in
this issue of the Journal of Thoracic and Cardiovascular
Surgery, sought to determine whether mutations in TP53
were associated with differential survival outcomes after
neoadjuvant cisplatin and 5-fluorouracil chemotherapy
followed by esophagectomy. TP53 genotyping identified
18 patients with TP53 mutations and 18 with normal
TP53 genotype. All patients were evaluated on an
intention-to-treat basis, although only 27 patients under-
went esophagectomy; 8 patients had disease progression
on chemotherapy and 1 had a complete response and
declined esophagectomy. Overall and tumor-specific
survivals were stratified by TP53 status and compared;
patients with TP53 mutation had significantly worse sur-
vival (median, 8.6 vs 26.2 months) and were twice as likely
to be dead at each follow-up interval than patients with
normal TP53. The study results suggest a lack of response
in the population with TP53 mutation, but Kandioler and
colleagues conclude that further validation is needed.
Several study strengths warrant highlighting. First, all
patients were treated with cisplatin and 5-fluorouracil.
Both agents rely on induction of DNA damage, a potent
trigger for activation of the TP53 gene, for therapeutic
effect. In the setting of a TP53 mutation, DNA damage
would not activate TP53, providing a biologically plausible
explanation for lack of treatment response. Second, p53
status is assessed at a genomic rather than at a protein level,
eliminating the potential biases noted by Zhang and
colleagues2 in their meta-analysis. The analysis is also
correctly based on intention-to-treat regardless of esopha-
gectomy, allowing close examination of the relationship
between TP53 mutation and response to treatment. All 8
patients with progression (no esophagectomy) had TP53
mutations, as did 6 of 7 patients with radiographically stable
disease who underwent esophagectomy (P<.0001). The 3
patients with complete response had normal TP53. Addi-
tional strengths include complete patient follow-up of
long duration (median, 87.4 months) and appropriately
circumspect study conclusions that take into account the
study limitations.
The weaknesses of the study of Kandioler and colleagues
include small study size, relatively high perioperativeThe Journal of Thoracic and Carmortality (11%), mixed histologic tumor types (squamous
cell and adenocarcinoma), and inadequate clinical staging.
The limitations of computed tomographic scanning for
depth of tumor invasion and nodal metastasis are well
described; tumor-stage misclassification is as high as
58%.3 Misclassification can be either overstaging or under-
staging, and at a minimum endoscopic ultrasonographic and
positron emission tomographic testing should be included
in the pretreatment clinical staging assessment. Some sur-
geons also recommend routine laparoscopic staging before
neoadjuvant therapy to lessen the significant rate of
misclassification.4,5
In summary, these findings have potentially significant
implications for pretreatment decision making for patients
with esophageal cancer. If validated, phenotyping of the
TP53 gene with pretreatment tumor biopsies may allow
tailored therapy. Whether this means primary esophagec-
tomy, an alternate chemotherapeutic regimen, or palliative
definitive chemoradiation, the potential benefit lies in opti-
mizing outcomes while reducing the morbidity and mortal-
ity of treatments without measurable, proven benefit to the
individual patient. Definitive conclusions regarding the
prognostic role of TP53 remain to be established, but the
study of Kandioler and colleagues suggests a potential
prognostic role that warrants further study. Toward this
end, enrollment of 168 patients in the p53 Adapted Neoad-
juvant Chemotherapy for Operable Esophageal Cancer
(PANCHO) trial was recently completed. If the study design
addresses the weaknesses of the current study of Kandioler
and colleagues, particularly with regard to the issues of clin-
ical staging and histologic subtypes, more definitive assess-
ment of the classification accuracy and positive and
negative predictive values of p53 for response to chemo-
therapy may be possible. Although a single crystal ball
for predicting response to chemotherapy may not even
exist, mutations of the p53 gene may prove to be an impor-
tant tool for stratifying patients into appropriate treatment
regimens.
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